Azimuth Capital Management LLC grew its holdings in shares of Becton Dickinson (NYSE:BDX) by 64.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 36,091 shares of the medical instruments supplier’s stock after acquiring an additional 14,108 shares during the period. Azimuth Capital Management LLC’s holdings in Becton Dickinson were worth $7,821,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. MUFG Securities EMEA plc bought a new position in shares of Becton Dickinson during the first quarter valued at $11,919,000. BlackRock Inc. raised its stake in shares of Becton Dickinson by 6.0% during the fourth quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after acquiring an additional 1,071,288 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its stake in shares of Becton Dickinson by 11.9% during the first quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 39,465 shares of the medical instruments supplier’s stock valued at $8,348,000 after acquiring an additional 4,203 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Becton Dickinson by 1,392.4% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,535 shares of the medical instruments supplier’s stock valued at $6,184,000 after acquiring an additional 26,623 shares during the last quarter. Finally, Norinchukin Bank The raised its stake in shares of Becton Dickinson by 2.7% during the first quarter. Norinchukin Bank The now owns 144,476 shares of the medical instruments supplier’s stock valued at $31,308,000 after acquiring an additional 3,816 shares during the last quarter. 84.45% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on BDX shares. Citigroup raised shares of Becton Dickinson from a “neutral” rating to a “buy” rating and raised their price target for the company from $237.00 to $251.00 in a research note on Tuesday, April 10th. Morgan Stanley raised their price target on shares of Becton Dickinson from $245.00 to $250.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 7th. ValuEngine raised shares of Becton Dickinson from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. Zacks Investment Research downgraded shares of Becton Dickinson from a “buy” rating to a “hold” rating in a research note on Tuesday, March 6th. Finally, BMO Capital Markets started coverage on shares of Becton Dickinson in a research note on Monday, March 5th. They set a “market perform” rating and a $249.00 target price for the company. Six equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $241.19.

In related news, Director David F. Melcher purchased 500 shares of the firm’s stock in a transaction on Monday, May 7th. The stock was purchased at an average cost of $225.07 per share, with a total value of $112,535.00. Following the completion of the purchase, the director now owns 2,728 shares in the company, valued at approximately $613,990.96. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas E. Polen, Jr. sold 1,877 shares of Becton Dickinson stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $227.00, for a total transaction of $426,079.00. Following the completion of the sale, the executive vice president now directly owns 15,387 shares of the company’s stock, valued at $3,492,849. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,214 shares of company stock valued at $7,338,413. Insiders own 1.00% of the company’s stock.

BDX opened at $221.59 on Friday. Becton Dickinson has a 1-year low of $185.33 and a 1-year high of $248.39. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $58.76 billion, a price-to-earnings ratio of 23.37, a P/E/G ratio of 1.53 and a beta of 1.15.

Becton Dickinson (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 3rd. The medical instruments supplier reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.02. Becton Dickinson had a negative net margin of 0.46% and a positive return on equity of 14.27%. The firm had revenue of $4.22 billion during the quarter, compared to the consensus estimate of $4.12 billion. During the same period in the previous year, the firm posted $2.30 earnings per share. The business’s revenue was up 42.2% compared to the same quarter last year. equities analysts predict that Becton Dickinson will post 10.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 8th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.35%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson’s dividend payout ratio (DPR) is currently 31.65%.

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson (NYSE:BDX)

Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.